All-trans  ||| S:0 E:10 ||| JJ
retinoic  ||| S:10 E:19 ||| JJ
acid  ||| S:19 E:24 ||| NN
enhances  ||| S:24 E:33 ||| VBZ
bystander  ||| S:33 E:43 ||| JJ
effect  ||| S:43 E:50 ||| NN
of  ||| S:50 E:53 ||| IN
suicide  ||| S:53 E:61 ||| JJ
gene  ||| S:61 E:66 ||| NN
therapy  ||| S:66 E:74 ||| NN
in  ||| S:74 E:77 ||| IN
the  ||| S:77 E:81 ||| DT
treatment  ||| S:81 E:91 ||| NN
of  ||| S:91 E:94 ||| IN
breast  ||| S:94 E:101 ||| JJ
cancer  ||| S:101 E:108 ||| NN
All-trans  ||| S:108 E:118 ||| JJ
retinoic  ||| S:118 E:127 ||| JJ
acid  ||| S:127 E:132 ||| NN
( ||| S:132 E:133 ||| -LRB-
ATRA ||| S:133 E:137 ||| NNP
)  ||| S:137 E:139 ||| -RRB-
has  ||| S:139 E:143 ||| VBZ
been  ||| S:143 E:148 ||| VBN
shown  ||| S:148 E:154 ||| VBN
to  ||| S:154 E:157 ||| TO
enhance  ||| S:157 E:165 ||| VB
the  ||| S:165 E:169 ||| DT
expression  ||| S:169 E:180 ||| NN
of  ||| S:180 E:183 ||| IN
connexinÂ 43  ||| S:183 E:195 ||| NNP
( ||| S:195 E:196 ||| -LRB-
Cx43 ||| S:196 E:200 ||| NNP
)  ||| S:200 E:202 ||| -RRB-
and  ||| S:202 E:206 ||| CC
the  ||| S:206 E:210 ||| DT
bystander  ||| S:210 E:220 ||| JJ
effect  ||| S:220 E:227 ||| NN
( ||| S:227 E:228 ||| -LRB-
BSE ||| S:228 E:231 ||| NNP
)  ||| S:231 E:233 ||| -RRB-
in  ||| S:233 E:236 ||| IN
suicide  ||| S:236 E:244 ||| JJ
gene  ||| S:244 E:249 ||| NN
therapy ||| S:249 E:256 ||| NN
.  ||| S:256 E:258 ||| .
These  ||| S:258 E:264 ||| DT
in  ||| S:264 E:267 ||| IN
turn  ||| S:267 E:272 ||| RB
improve  ||| S:272 E:280 ||| VB
effects  ||| S:280 E:288 ||| NNS
of  ||| S:288 E:291 ||| IN
suicide  ||| S:291 E:299 ||| JJ
gene  ||| S:299 E:304 ||| NN
therapies  ||| S:304 E:314 ||| NNS
for  ||| S:314 E:318 ||| IN
several  ||| S:318 E:326 ||| JJ
tumor  ||| S:326 E:332 ||| NN
types ||| S:332 E:337 ||| NNS
.  ||| S:337 E:339 ||| .
However ||| S:339 E:346 ||| RB
,  ||| S:346 E:348 ||| ,
whether  ||| S:348 E:356 ||| IN
ATRA  ||| S:356 E:361 ||| NNP
can  ||| S:361 E:365 ||| MD
improve  ||| S:365 E:373 ||| VB
BSE  ||| S:373 E:377 ||| NNP
remains  ||| S:377 E:385 ||| VBZ
unclear  ||| S:385 E:393 ||| JJ
in  ||| S:393 E:396 ||| IN
suicide  ||| S:396 E:404 ||| JJ
gene  ||| S:404 E:409 ||| NN
therapy  ||| S:409 E:417 ||| NN
for  ||| S:417 E:421 ||| IN
breast  ||| S:421 E:428 ||| JJ
cancer ||| S:428 E:434 ||| NN
.  ||| S:434 E:436 ||| .
In  ||| S:436 E:439 ||| IN
the  ||| S:439 E:443 ||| DT
present  ||| S:443 E:451 ||| JJ
study ||| S:451 E:456 ||| NN
,  ||| S:456 E:458 ||| ,
MCF-7 ||| S:458 E:463 ||| NNP
,  ||| S:463 E:465 ||| ,
human  ||| S:465 E:471 ||| JJ
breast  ||| S:471 E:478 ||| NN
cancer  ||| S:478 E:485 ||| NN
cells  ||| S:485 E:491 ||| NNS
were  ||| S:491 E:496 ||| VBD
treated  ||| S:496 E:504 ||| VBN
with  ||| S:504 E:509 ||| IN
ATRA  ||| S:509 E:514 ||| NNP
in  ||| S:514 E:517 ||| IN
combination  ||| S:517 E:529 ||| NN
with  ||| S:529 E:534 ||| IN
a  ||| S:534 E:536 ||| DT
VEGFP-TK ||| S:536 E:544 ||| JJ
/ ||| S:544 E:545 ||| NNP
CD  ||| S:545 E:548 ||| NNP
gene  ||| S:548 E:553 ||| NN
suicide  ||| S:553 E:561 ||| NN
system  ||| S:561 E:568 ||| NN
developed  ||| S:568 E:578 ||| VBN
by  ||| S:578 E:581 ||| IN
our  ||| S:581 E:585 ||| PRP$
group ||| S:585 E:590 ||| NN
.  ||| S:590 E:592 ||| .
We  ||| S:592 E:595 ||| PRP
found  ||| S:595 E:601 ||| VBD
that  ||| S:601 E:606 ||| IN
this  ||| S:606 E:611 ||| DT
combination  ||| S:611 E:623 ||| NN
enhances  ||| S:623 E:632 ||| VBZ
the  ||| S:632 E:636 ||| DT
efficiency  ||| S:636 E:647 ||| NN
of  ||| S:647 E:650 ||| IN
cell  ||| S:650 E:655 ||| NN
killing  ||| S:655 E:663 ||| NN
and  ||| S:663 E:667 ||| CC
apoptosis  ||| S:667 E:677 ||| NN
of  ||| S:677 E:680 ||| IN
breast  ||| S:680 E:687 ||| JJ
cancer  ||| S:687 E:694 ||| NN
by  ||| S:694 E:697 ||| IN
strengthening  ||| S:697 E:711 ||| VBG
the  ||| S:711 E:715 ||| DT
BSE  ||| S:715 E:719 ||| NNP
in  ||| S:719 E:722 ||| IN
vitro ||| S:722 E:727 ||| NN
.  ||| S:727 E:729 ||| .
ATRA  ||| S:729 E:734 ||| NNP
also  ||| S:734 E:739 ||| RB
promotes  ||| S:739 E:748 ||| FW
gap  ||| S:748 E:752 ||| FW
junction  ||| S:752 E:761 ||| FW
intercellular  ||| S:761 E:775 ||| FW
communication  ||| S:775 E:789 ||| FW
( ||| S:789 E:790 ||| -LRB-
GJIC ||| S:790 E:794 ||| NNP
)  ||| S:794 E:796 ||| -RRB-
in  ||| S:796 E:799 ||| IN
MCF-7  ||| S:799 E:805 ||| CD
cells  ||| S:805 E:811 ||| NNS
by  ||| S:811 E:814 ||| IN
upregulation  ||| S:814 E:827 ||| NN
of  ||| S:827 E:830 ||| IN
the  ||| S:830 E:834 ||| DT
connexin  ||| S:834 E:843 ||| JJ
43  ||| S:843 E:846 ||| CD
mRNA  ||| S:846 E:851 ||| JJ
and  ||| S:851 E:855 ||| CC
protein  ||| S:855 E:863 ||| NN
in  ||| S:863 E:866 ||| IN
MCF-7  ||| S:866 E:872 ||| CD
cells ||| S:872 E:877 ||| NNS
.  ||| S:877 E:879 ||| .
These  ||| S:879 E:885 ||| DT
results  ||| S:885 E:893 ||| NNS
indicate  ||| S:893 E:902 ||| VBP
that  ||| S:902 E:907 ||| DT
enhancement  ||| S:907 E:919 ||| NN
of  ||| S:919 E:922 ||| IN
GJIC  ||| S:922 E:927 ||| NNP
by  ||| S:927 E:930 ||| IN
ATRA  ||| S:930 E:935 ||| NNP
in  ||| S:935 E:938 ||| IN
suicide  ||| S:938 E:946 ||| JJ
gene  ||| S:946 E:951 ||| NN
system  ||| S:951 E:958 ||| NN
might  ||| S:958 E:964 ||| MD
serve  ||| S:964 E:970 ||| VB
as  ||| S:970 E:973 ||| IN
an  ||| S:973 E:976 ||| DT
attractive  ||| S:976 E:987 ||| JJ
and  ||| S:987 E:991 ||| CC
cost-effective  ||| S:991 E:1006 ||| JJ
strategy  ||| S:1006 E:1015 ||| NN
of  ||| S:1015 E:1018 ||| IN
therapy  ||| S:1018 E:1026 ||| NN
for  ||| S:1026 E:1030 ||| IN
breast  ||| S:1030 E:1037 ||| JJ
cancer  ||| S:1037 E:1044 ||| NN
cells ||| S:1044 E:1049 ||| NNS
.  ||| S:1049 E:1051 ||| .
